Homozygosity mapping provides supporting evidence of pathogenicity in recessive Mendelian disease

Genet Med. 2019 Apr;21(4):982-986. doi: 10.1038/s41436-018-0281-4. Epub 2018 Oct 3.

Abstract

Purpose: One of the greatest challenges currently facing those studying Mendelian disease is identifying the pathogenic variant from the long list produced by a next-generation sequencing test. We investigate the predictive ability of homozygosity mapping for identifying the regions likely to contain the causative variant.

Methods: We use 179 homozygous pathogenic variants from three independent cohorts to investigate the predictive power of homozygosity mapping.

Results: We demonstrate that homozygous pathogenic variants in our cohorts are disproportionately likely to be found within one of the largest regions of homozygosity: 80% of pathogenic variants are found in a homozygous region that is in the ten largest regions in a sample. The maximal predictive power is achieved in patients with <8% homozygosity and variants >3 Mb from a telomere; this gives an area under the curve (AUC) of 0.735 and results in 92% of the causative variants being in one of the ten largest homozygous regions.

Conclusion: This predictive power can be used to prioritize the list of candidate variants in gene discovery studies. When classifying a homozygous variant the size and rank of the region of homozygosity in which the candidate variant is located can also be considered as supporting evidence for pathogenicity.

Keywords: ACMG guidelines; Mendelian disease; genetic diagnosis; recessive disease; variant interpretation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromosome Mapping / methods*
  • Female
  • Genetic Diseases, Inborn / diagnosis
  • Genetic Diseases, Inborn / genetics*
  • Genetic Diseases, Inborn / pathology
  • High-Throughput Nucleotide Sequencing / methods*
  • Homozygote
  • Humans
  • Male
  • Pedigree
  • Polymorphism, Single Nucleotide / genetics
  • Sequence Analysis, DNA